Godinho Kevin S, Rae Al, Windsor G David, Tilt Nicola, Rowan Tim G, Sunderland Simon J
Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK.
Vet Ther. 2005 Summer;6(2):96-112.
The efficacy of tulathromycin in the treatment of bovine respiratory disease (BRD) due to Mycoplasma bovis was determined following experimental infection. Two highly pathogenic strains of M. bovis (with minimum inhibitory concentration values for tulathromycin of 1 and >64 microg/ml) were inoculated into 145 calves. Four days after inoculation, calves with clinical BRD were treated subcutaneously with saline or tulathromycin (2.5 mg/kg). Compared with saline, BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves (P < .01). Tulathromycin was highly effective in the treatment of BRD due to M. bovis in calves regardless of the minimum inhibitory concentration of the challenge strain (1 or >64 microg/ml).
在实验性感染后，测定了泰拉霉素治疗牛支原体引起的牛呼吸道疾病（BRD）的疗效。将两株高致病性牛支原体菌株（泰拉霉素的最低抑菌浓度值分别为1和>64微克/毫升）接种到145头犊牛体内。接种后4天，对出现临床BRD的犊牛皮下注射生理盐水或泰拉霉素（2.5毫克/千克）。与生理盐水组相比，泰拉霉素治疗组犊牛与BRD相关的淘汰率、直肠温度峰值和肺部病变评分显著更低（P <.01）。无论攻毒菌株的最低抑菌浓度如何（1或>64微克/毫升），泰拉霉素在治疗犊牛由牛支原体引起的BRD方面都非常有效。
